exelixis - WTMnews.gr

Incorporation Year: -
No. of Employees: -

Address:
- - -
USA

Website: www.exelixis.com

About the company:

Articles

Date	Title
03/05/12 14:58:10	Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration
05/03/12 16:00:21	Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial
28/02/12 11:03:19	Dual Inhibition of MET and VEGF Signaling With Cabozantinib Blocks Tumor Invasiveness and Metastasis
10/02/12 19:50:11	Exelixis Announces Pricing of $60.5 Million Public Offering of Common Stock
03/02/12 19:14:16	Cabozantinib: Encouraging Activity in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma
25/01/12 09:21:16	Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular
29/11/11 00:26:48	Exelixis Signs CRADA With National Cancer Institute to Expand Development Plan of Cabozantinib
21/11/11 20:06:22	Exelixis Announces Initiation of Phase 2 Investigator-Sponsored Trial of Cabozantinib in Women
14/11/11 14:25:29	Exelixis' Cabozantinib Phase 2 Data Demonstrate Reduction in Bone Pain
01/11/11 16:05:39	Exelixis to Initiate Cabozantinib '306 Trial with Pain Endpoint in mCRPC
25/10/11 20:28:01	Exelixis Appoints Executive Vice President and Chief Commercial Officer
07/09/11 16:46:40	Exelixis Reaches Pre-Specified Number of Events for Final Data Analysis in EXAM Trial
05/08/11 12:49:18	Exelixis Announces Second Quarter 2011 Financial Results
07/07/11 06:52:10	Exelixis Provides Update on Cabozantinib Development Activities
07/06/11 10:29:21	Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity
24/05/11 09:19:49	Exelixis' Cabozantinib Phase 1 Clinical Trial Data published in Journal of of Clinical Oncology
04/05/11 10:56:45	Exelixis Announces First Quarter 2011 Financial Results
10/03/11 16:08:43	Exelixis Announces Pricing of $165.0 Million Public Offering of Common Stock
10/01/11 15:11:28	Exelixis' XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
18/11/10 14:47:20	Exelixis Reports Promising Interim Data from Patients with Castration-Resistant Prostate Cancer
05/11/10 11:43:31	Exelixis Announces Third Quarter 2010 Financial Results
11/10/10 10:34:41	Exelixis Licenses Programs to Bristol-Myers Squibb Company
06/09/10 08:28:40	Exelixis Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06/08/10 08:37:59	Exelixis Announces Second Quarter 2010 Financial Results
01/07/10 07:43:06	Exelixis Announces Appointment of New CEO
21/06/10 09:57:55	Exelixis Regains Full Rights to Develop and Commercialize XL184
07/06/10 17:20:01	Exelixis Reports Updated Data from Multiple Clinical Trials of the PI3K Inhibitor XL147
07/06/10 08:26:01	Exelixis Reports Updated Data from Multiple Clinical Trials of the Dual PI3K & mTOR Inhibitor XL765
03/06/10 14:56:58	Exelixis to Raise $160 Million
21/05/10 08:03:30	Exelixis Reports Encouraging Interim Data from an Ongoing Adaptive Randomized Discontinuation Trial
12/05/10 06:29:27	Exelixis Announces First Quarter 2010 Financial Results
03/03/10 07:46:49	Exelixis Announces March 9 Webcast of Its Fourth Quarter and Full Year 2009 Financial Results Confer
05/02/10 13:14:26	Exelixis Announces February 9 Webcast of Presentation at the 12th Annual BioCEO

PR Manager

First Name:	x
Last Name:	x
Position:	x

HR Manager

First Name:	-
Last Name:	-
Position:	-

Additional Info

Website:	www.exelixis.com
Email:	-
Address:	-
City:	-
Zip Code:	-
Country:	USA
Phone #:	-
Fax #:	-